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Abstract 
New dioxomolybdenum(VI) complexes were obtained by the reaction of [MoO2(acac)2] 
with thiosemicarbazone ligands derived from 3-thiosemicarbazide and  
4-(diethylamino)salicylaldehyde (H2L
1
), 2-hydroxy-3-methoxybenzaldehyde (H2L
2
) or 
2-hydroxy-1-naphthaldehyde (H2L
3
). In all complexes thiosemicarbazonato ligands are 
coordinated to molybdenum as tridentate ONS-donors. Octahedral coordination of each 
molybdenum atom is completed by methanol molecule (in 1a-3a) or by oxygen atom of 
Mo=O unit from the neighbouring molecule (in 1-3). All complexes were characterized 
by means of chemical analyses, IR spectroscopy, TG and NMR measurements.  The 
molecular structures of the ligand H2L
2
 and complex [MoO2L
2
(CH3OH)]·CH3OH (2a) 
have been determined by single crystal X-ray crystallography. The characterisation of 
thiosemicarbazonato molybdenum(VI) complexes (1-4) as well as of the  
4-phenylthisemicarbazonato molybdenum(VI) complexes (5-8) 
 
in aqueous medium 
revealed that upon dissolving complexes in water, most likely to some extent 
dissociation took place, although experimental data didn’t allow exact quantification of 
dissociation. The antiproliferative effects of studied molybdenum(VI) complexes (1-8) 
on the human cell lines were identical to the activity of their corresponding ligands. 
 
Keywords: thiosemicarbazone; molybdenum(VI) complexes; X-ray crystal structures; 
antiproliferative effects; tumour cell lines. 
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1. Introduction 
 
Since first study on thiosemicarbazones activity against Mycobacterium tuberculosis 
[1] many other biological activities of this type molecules have been described, for 
instance antitumoral, antifungal and antiviral [2,3]. Thiosemicarbazones, in their neutral 
or deprotonated form, behave as a ONS/NNS tridentate or tetradentate chelate towards 
metal ions essential for life. Important finding was that a NNS thiosemicarbazone ligand 
system was a common feature of all compounds with carcinostatic potency. Some 
thiosemicarbazones, such as marboran or triapine, are already used in medical practice. 
Recent discovery of the antitumor effects of metal complexes and their potential use in 
cancer diseases have received increasing attention [4,5]. Metal complexes show an 
activity which, if compared with that of the corresponding ligands, is of the same order 
of magnitude and often larger [6]. 
Metal chelation is an important process useful to afford new chemical features to metal 
complexes in order to make them suitable for pharmacological applications. Many 
useful drugs contain metal-binding sites, which may alter the physiological profile of 
the free species. Some of them increase their activity by their ability to form chelates 
with specific metal ion. For example, cellular uptake of copper-chelated 
thiosemicarbazones is advanced over that of free ligand because of the enhanced 
lipophilicity of the metal-drug combination [7].  
The transition element molybdenum (Mo) is of essential importance for nearly all 
biological systems as it is required by enzymes catalyzing diverse key reactions in the 
global carbon, sulphur and nitrogen metabolism. It occurs in a wide range of 
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metalloenzymes in bacteria, fungi, algae, plants and animals where it forms part of the 
active sites of these enzymes. The active site includes the metal atom coordinated to 
one or two pyranopterin molecules and to a variable number of ligands such as oxygen, 
sulphur and selenium atoms
 
 [8,9]. Diverse class of molybdenum complexes were 
prepared, tested and developed for various pharmaceutical purposes, whereby their 
anticancer activities gained special attention. For example, tetrathiomolybdate (TM) is 
an anticopper drug under development for treating Wilson's disease. Its mechanism of 
action involves forming a tight tripartite complex in the blood with serum albumin and 
available copper. In addition, it has been shown that lowering copper levels with TM 
produces an antiangiogenic, anticancer effect, probably due to inhibition of many 
copper-dependent proangiogenic cytokines. Therefore, it has shown a promising role in 
suppressing tumor angiogenesis, retinal neovascularization, and pathologic 
inflammatory conditions [10,11].  
Additionally, polyoxometalates, negatively charged inorganic substances which contain 
early transitional metal ions and make a cluster with the surrounding oxygen atoms are 
a large class of inorganic compounds with great molecular diversity and significant 
potential applications in chemistry and medicine [12]. Yamase had reported that 
significant antitumoral effect of polyoxomolybdates, especially 
[NH3Pr
i
]6[Mo7O24]·3H2O (PM-8) was found against MX-1 murine mammary cancer 
cell line, Meth A sarcoma and MM46 adenocarcinoma [13]. Our group also showed 
that γ-octamolybdates containing aminoacids and peptides showed differential cell-
growth inhibition in a dose-dependent manner selectively on hepatocellular carcinoma 
cell line (HepG2) and breast cancer cell line (MCF-7) [14]. 
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Furthermore, metallocene diacido complexes containing transition metals, such as 
titanium, vanadium, niobium, zirconium, and molybdenum, also exhibit variable 
antitumor activity for a wide spectrum of murine and human tumors with reduced 
toxicity when compared with cisplatin [15].  
In our previous paper [16], we have reported synthesis and characterisation of several 
new thiosemicarbazone derivatives, as well as strong antiproliferative activity of these 
compounds against several human tumor cell lines. In a continuation of our work 
concerning the coordination chemistry [17,18,19] and biological activity of 
thiosemicarbazones [16] we have prepared several new molybdenum(VI) complexes 
(1-3 and 1a-3a) (Scheme 1).  
 
Scheme 1.  
 
The complexes [MoO2L]n (1-3, described in here-presented study and 4-8, known from 
our previous investigation [17,18]) were also tested for their antiproliferative ability 
against selected human tumor cell lines and compared to parent thiosemicabazone 
ligands.  Here presented synthetic, structural and biological studies have been carried 
out in order to obtain information on structure-activity relationships for systems 
involving molybdenum(VI) ions.  
 
2. Experimental  
General remarks: The starting acetylacetonato complex [MoO2(acac)2] and 
thiosemicarbazones (HL
1
-HL
3
) were prepared as described in the literature [20,16]. 
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The complexes [MoO2L]n (4-8) were synthesized according to the published procedure 
[17,18] All aldehydes and thiosemicarbazide were of reagent grade and used as 
purchased. Methanol was dried using magnesium shavings and iodine and then 
distilled. Acetonitrile and dichloromethane were dried over P2O5 and distilled. C, H and 
N analyses were provided by the Analytical Services Laboratory of Ruđer Bošković 
Institute, Zagreb. Molybdenum was determined according to the method described in 
literature [21].  
IR spectra were recorded as KBr pellets using Perkin-Elmer Fourier-Transform 
Spectrum RX1 Spectrophotometer in the region 4500-450 cm
-1
. Thermogravimetric 
analyses were measured on a Mettler TG 50 thermobalance using aluminum crucibles 
under oxygen atmosphere with a heating rate of 5 °C min-1. For all experiments the 
temperature ranged from 25 to 600 C. The results were developed by applying the 
Mettler STAR
e
 6,1. programme. Thermal analysis data are given in Table 1. 
 
2.1. Synthesis of complexes 
2.1.1. Synthesis of [MoO2L]n (1-3)  
Molybdenum(VI) complexes were obtained by reacting an acetonitrile (20 mL) 
suspension of [MoO2(acac)2] (0.46 mmol) and stehiometric amount of the appropriate 
ligand H2L (H2L
1
, H2L
2
 or H2L
3
). The reaction mixture was slowly refluxed for 7 h 
and the complexes as dark red (0.15g, 1), orange (0.11g, 2) and yellowish-brown 
(0.12g, 3) solids were precipitated. The obtained products were collected by filtration, 
washed well with acetonitrile and dried in vacuum. 
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(1) [MoO2(C12H16N4OS)]n: Yield. 83%. Anal. Calcd. for: C12H16MoN4O3S; C, 36.74; 
H, 4.11; N, 14.28; S, 8.17; Mo, 24.46%; Found: C, 36.79; H, 3.98; N, 14.29; S, 8.34; 
Mo, 24.52%. IR (cm
-1
) in KBr: 1633(s), 1610(vs), 1572(vs), 1507(vs), 1410(m), 
1352(s), 1248(s), 1138(s), 933(s), 846(vs). 
 (2) [MoO2(C9H9N3O2S)]n: Yield. 68%. Anal. Calcd. for: C9H9MoN3O4S; C, 30.78; H, 
2.58; N, 11.97; S, 9.13; Mo, 27.32%; Found: C, 30.83; H, 2.70; N, 11.59; S, 9.35; Mo, 
27.00%. IR (cm
-1
) in KBr: 1624(s), 1567(m), 1538(s), 1529(s), 1328(m), 1266(s), 
935(s), 911(s) 806(vs), 755(s). 
(3) [MoO2(C12H9N3OS)]n: Yield. 82%. Anal. Calcd. for: C12H9MoN3O3S; C, 38.83; H, 
2.44; N, 11.32; S, 8.64; Mo, 25.84%; Found: C, 38.25; H, 2.58; N, 11.24; S, 8.73; Mo, 
23.38%.  IR (cm
-1
) in KBr: 1619(m), 1594(m), 1557(s), 1512(m), 1331(m), 1281(m), 
931(s), 916(m) 819(vs), 772(m). 
 
2.1.2.  Synthesis of [MoO2L(CH3OH)] (1a-3a)  
Complexes 1-3 (0.26 mmol) were dissolved in dry methanol and the solutions were 
warmed up for 4h (2 h for 3a). The solution was evaporated to one third of its volume 
under reduced pressure and left several days at room temperature.  
The obtained crystalline products (0.1 g, 1a dark red; 0.07 g, 2a orange, 0.07 g, 3a dark 
red) were collected by filtration, washed well with cold tetrachloromethane and dried in 
vacuum. 
 (1a) [MoO2(C12H16N4OS)(CH3OH)]: Yield. 55%. Anal.Calcd.for: C13H20MoN4O4S; C, 
36.80; H, 4.75; N, 13.20; S, 7.56; Mo, 22.61%; Found: C, 36.62; H, 4.25; N, 13.64; S, 
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7.20; Mo, 23.00%. IR (cm
-1
) in KBr: 1633(s), 1610(vs), 1573(vs), 1509(vs), 1352(s), 
1315(m), 1248(vs), 1138(s), 933(m). 
 (2a) [MoO2(C9H9N3O2S)(CH3OH)]: Yield. 46%. Anal.Calcd.for: C10H13MoN3O5S; C, 
31.34; H, 3.42; N, 10.96; S, 8.37; Mo, 25.03%; Found: C, 30.96; H, 3.07; N, 11.32; S, 
8.59; Mo, 24.92%. IR (cm
-1
) in KBr: 1626(s), 1594(m), 1563(m), 1514(s), 1460(s), 
1337(m), 1263(vs), 932(s), 901(vs). 
(3a) [MoO2(C12H9N3OS)(CH3OH)]: Yield. 38%. Anal.Calcd.for: C13H13MoN3O4S; C, 
38.72; H, 3.25; N, 10.42; S, 7.95; Mo, 23.79%; Found: C, 38.54; H, 3.41; N, 10.47; S, 
7.86; Mo, 23.52%. IR (cm
-1
) in KBr: 1616(s), 1593(s), 1578(w), 1550(s), 1508(m), 
1332(m),  938(m), 891(s). 
 
2.2. X-ray crystallography 
 Data collection was performed on Oxford Diffraction Xcalibur CCD diffractometer 
with graphite-monochromated Mo Kα radiation at 293 K, using ω-scans at crystal to 
detector distance of 60 mm. Details of data collection and crystal structure refinement 
are summarized in Table 2. 
The programs CrysAlis CCD and CrysAlis RED [22] were used for data collection, cell 
refinement and data reduction. The structure was solved by direct methods. Refinement 
procedure by full-matrix least squares methods based on F
2
 values against all 
reflections included anisotropic displacement parameters for all non-H atoms. The 
positions of hydrogen atoms were determined on stereochemical grounds, each riding 
on their carrier atom. Calculations were performed with SHELXS97 [23] and 
SHELXL97 [24] (both operating under WinGX [25] program package). The molecular 
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graphics were done with PLATON98 [26] and Mercury [27]. Selected bond distances 
and valence angles are listed in Table 3. 
 
2.3. NMR  spectroscopy 
One- and two-dimensional (
1
H, APT, gCOSY, gHSQC and gHMBC) NMR spectra 
were recorded at ambient temperature on the Avance DRX500 spectrometer using a 5 
mm diameter inverse detection probe with z-gradient. The spectra were recorded in 
DMSO-d6 with the sample concentration of 20 mg mL
-1
 and TMS as the internal 
standard. Typical spectral conditions for one-dimensional 
1
H and 
13
C (APT) spectra 
were as follows. The spectra were recorded using 64K data points and spectral widths 
of 6200 Hz and 20000 Hz for proton and carbon (APT) experiments, respectively. 
Digital resolution was 0.10 Hz and 0.30 Hz per point, respectively. The number of 
scans was 8-16 for 
1
H and 1000-3000 for APT spectra. 2D gradient selected COSY 
spectra were acquired with a sweep width of 6000 Hz in both dimensions into 2K data 
points with 256 increments. Spectra were zero-filled in the f1 dimension to 1K and 
processed using an unshifted sine bell window function. Digital resolution was 3.91 Hz 
per point in both dimensions.  The gradient selected inverse 
1
H-
13
C correlation 
experiments, gHSQC and gHMBC were recorded at 125.77 MHz using the acquisition 
matrix of 1K x 256 with 32 scans and processed with 2K x 1K transformed matrix. The 
sweep width was 7500 Hz in f2 dimension and 31500 Hz in f1 dimension for both 
experiments. Spectra were processed with a shifted sine bell window function and 
linear prediction. Digital resolution was 3.25 Hz per point and 30.70 Hz per point in f2 
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and f1, respectively. HMBC spectra were recorded using transfer delay for the 
evolution of long range C-H couplings of 60 ms. 
 
2.4. Spectrophotometric experiments 
The electronic absorption spectra were recorded on Varian Cary 100 Bio spectrometer, 
and fluorescence emission spectra were recorded on Varian Eclipse fluorimeter, in all 
cases using quartz cuvettes (1 cm). The measurements were performed in the aqueous 
buffer solution (pH = 7.0; sodium cacodylate buffer, I = 0.05 mol dm
-3
). Under the 
experimental conditions used the absorbance and fluorescence intensities of studied 
compounds were proportional to their concentrations. Titrations of H2L
1
-H2L
8
 with 
dioxobis(2,4-pentanedionato)molybdenum(VI), [MoO2(acac)2] were performed by 
adding aliquots of  [MoO2(acac)2] into cuvette with aqueous solution of the 
corresponding H2L
 
followed by measuring the spectrum. Binding constants (logKs) and 
complex stoichiometries were calculated by processing titration data (complete spectra) 
by Specfit program [28].  
 
2.5. Interactions with ct-DNA 
The calf thymus DNA (ct-DNA) was purchased from Aldrich, dissolved in the sodium 
cacodylate buffer, I = 0.05 mol dm
-3
, pH = 7.0, additionally sonicated and filtered 
through a 0.45 µm filter and the concentration of corresponding solution determined 
spectroscopically as the concentration of phosphates. Spectroscopic titrations were 
performed by adding portions of ct-DNA solution into the solution of the studied 
compound. Thermal melting curves for ct-DNA and its complexes with studied species 
 11 
were determined as previously described
 
by following the absorption change at 260 nm 
as a function of temperature [16].
 
The absorbance of the ligand was subtracted from 
every curve, and the absorbance scale was normalized. Obtained Tm values are the 
midpoints of the transition curves, determined from the maximum of the first derivative 
or graphically by a tangent method. Given Tm values were calculated subtracting Tm 
of the free nucleic acid from Tm of complex. Every Tm value here reported was the 
average of at least two measurements, the error in Tm is  0.5 °C. 
 
2.6. Antiproliferative activity assay.  
The HeLa (cervical carcinoma), Hep-2 (laryngeal carcinoma), MCF-7 (breast 
carcinoma), SW620 (colon carcinoma), MiaPaCa-2 (pancreatic carcinoma) and Hep-2 
(laringeal carcinoma) and WI 38 (normal diploid fibroblasts) cells (obtained from 
American Type Culture Collection (ATCC, Rockville, MD, USA) were cultured as 
monolayers and maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, 100 U/ml 
penicillin and 100 μg/mL streptomycin in a humidified atmosphere with 5% CO2 at 
37˚C. The growth inhibition activity was assessed as described previously, according to 
the slightly modified procedure of the National Cancer Institute, Developmental 
Therapeutics Program [16]. The cells were inoculated onto standard 96-well microtiter 
plates on day 0. The cell concentrations were adjusted according to the cell population 
doubling time (PDT): 1  104/mL for HeLa, Hep-2, MiaPaCa-2 and SW620 cell lines 
(PDT = 20-24 h), 2  104/mL for MCF-7 cell line (PDT = 33 h) and 3  104/mL for WI 
38 (PDT = 47 h). Test agents were then added in five dilutions (10
-8
 to 5  10-6 mol/l) 
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and incubated for a further 72 hours. Working dilutions were freshly prepared on the 
day of testing. After 72 hours of incubation, the cell growth rate was evaluated by 
performing the MTT assay, which detects dehydrogenase activity in viable cells. Each 
test was performed in quadruplicate in three individual experiments. The results are 
expressed as IC50, which is the concentration necessary for 50% of inhibition. The IC50 
values for each compound are calculated from concentration-response curves using 
linear regression analysis by fitting the test concentrations that give PG values above 
and below the reference value (i.e. 50%). If however, for a given cell line all of the 
tested concentrations produce PGs exceeding the respective reference level of effect 
(e.g. PG value of 50), then the highest tested concentration is assigned as the default 
value, which is preceded by a ">" sign. Each result is a mean value from three separate 
experiments. 
 
3. Results and discussion 
3. 1. Synthesis 
As a part of our studies on molybdenum(VI) complexes with oxygen, sulphur and/or 
nitrogen donor ligands new polynuclear [MoO2L]n (1-3) and mononuclear 
[MoO2L(CH3OH)] complexes (1a-3a) were isolated (Scheme 1). Polynuclear 
molybdenum(VI) complexes were obtained in the reaction of [MoO2(acac)2] and 
equimolar amount of the appropriate thiosemicarbazone ligands derived from  
4-(diethylamino)salicylaldehyde (H2L
1
) hydroxy-3-methoxybenzaldehyde (H2L
2
) or  
2-hydroxy-1-naphthaldehyde (H2L
3
)
 
in acetonitrile. Compounds 1, 2 and 3 are dark red, 
orange or yellowish-brown powders, respectively and their polynuclear structure 
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changes to monomeric in methanolic solution. The complexes 4-8 were prepared in a 
similar way, as already described in the literature [17, 18]. The complexes of general 
formulae [MoO2L(CH3OH)] (L = L
1
, L
2
 and L
3
) were isolated from concentrated 
methanolic solutions.  
 
Infrared spectra and thermal analyses:  In the IR spectra of complexes [MoO2L]n (1-3) 
the intense bands 775- 846 cm
-1
 region and a single strong absorption band found in the 
891-964 cm
-1 region were assigned to the Mo=O···Mo bridging and terminal Mo=O 
groups. The appearance of the νasym(MoO2) and νsym(MoO2) within the 926-938 cm
-1
 
and 891-901 cm
-1
 regions, respectively and the absence of the band, in the 770-850 
cm
−1
 region, indicative of intermolecular metal···oxygen interaction is characteristic of 
the spectra of monomeric complexes [MoO2L(CH3OH)]. The bands in the 1633-1514 
cm
-1
 region were assigned to the stretching vibrations of C=N and C-Ophenolic 
thiosemicarbazone groups, respectively. These and all other frequencies founded in the 
IR spectra of complexes are in accordance to the literature data for the same type of 
complexes [29,30]. 
According to the X-ray structure analysis complex 2a is solvated with one methanol 
molecule [MoO2L
2
(CH3OH)]·CH3OH. The crystals were loosing solvent at room 
temperature so that they were left in a desiccator up to constant weight and analyzed as 
unsolvated species [MoO2L
2
(CH3OH)]. Thermal analyses of all prepared 
[MoO2L(CH3OH)] complexes (1a-3a) revealed two main processes: loss of coordinated 
methanol molecule in first step and decomposition of complex on further heating. The 
solid residues were identified as MoO3.  
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TABLE 1 
 
3.2. Molecular and crystal structures 
Selected bond distances and angles are given in Table 3. An ORTEP wiew of the H2L
2
 
is shown in Fig. 1. The 2-hydroxy-3-methoxybenzaldehyde thiosemicarbazone 
molecule (H2L
2
) exists in the keto (thione) tautomeric form [C–S amounts 1.697(3) Å], 
with the trans configuration of the S1 atom with respect to the N3 and with N1 in the 
cis configuration with respect to the N3. Molecule is built of two planar moieties: 
aliphatic thiosemicarbazone part (defined by C1, C2, N1, N2, N3 and S1 atoms with 
maximum deviation from mean plane of −0.031(2) Å for N3) and methoxyphenolic 
part (defined by remaining non-hydrogen atoms with maximum deviation from mean 
plane of −0.013(4) Å for C7). Dihedral angle between these two planes is 12.78°. This 
mild inclination mostly affects crystal packing because it brings molecules in good 
position for hydrogen bonding formation and saturation. The bond distances within 
thiosemicarbazone chain show π-electron delocalization. Although the 2-hydroxy-3-
methoxybenzaldehyde thiosemicarbazone is highly related to the other salycilaldehyde 
thiosemicarbazone derivatives [31], the intramolecular hydrogen bond between 
hydroxyl group and N3 atom is not observed. This can be due the presence of another 
hydrogen bond acceptor as suggested in some earlier papers.  
 
Figure 1.  
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The crystal packing is characterized by hydrogen bonding interactions between the 
molecules. Fig. 2 depicts centrosymmetric 2
2 (8)R dimers which are held together by 
hydrogen bonds of N2–H2N···S1i type (i = 1−x, 1−y, −z) forming layers which are 
parallel to the crystallographic (20) plane. Layers are interconnected with hydrogen 
bonds of N1–H1NA···O3ii (ii = 1−x, y+1/2, 1/2−z) and O3–H3O···S1iii (iii = 1−x, 
y−1/2, 1/2−z) type.  
 
Figure 2.  
 
In the molecular structure of the compound [MoO2L
2
(CH3OH)]·CH3OH (2a), the 
molybdenum atom displays a slightly distorted octahedral coordination involving 
oxygen, sulphur and nitrogen atoms from an 2-hydroxy-3-methoxybenzaldehyde 
thiosemicarbazone acting as a tridentate ligand, two oxygen atoms from cis-[MoO2]
2+
 
unit and solvent molecule (Fig. 3, Table 3). Like in almost all cis-dioxo molybdenum 
coordination compounds, the central metal ion is not in the centre of the octahedron but 
is shifted towards terminal oxygen atoms by the same degree. The distance from the 
plane defined by S1, N3, O1 and O3 is 0.3624(4) Å. Because of the above mentioned 
fact, five and six-membered chelate rings are not planar which indicate non-planarity of 
the ligand in the complex [MoO2L
2
(CH3OH)]·CH3OH (2a) 
 
Figure 3. 
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In [MoO2L
2
(CH3OH)]·CH3OH (2a) complex Mo–O distances of the [MoO2]
2+
 units are 
mostly as expected, indicating that they are double bonds. In the regular octahedrons, 
angles between cis ligands are 90°. Observed O=Mo=O angle is significantly larger 
than regular one, indicating greater repulsion between oxygen atoms closely bounded to 
the central metal atom. Coordination of the molybdenum(VI) ion by the solvent 
molecule is weakened which is reflected in the lengthening of Mo–O5 distance (Table 
3) in comparison with Mo–donor atom bond lengths found during survey of the 
Cambridge Structural Database [32]. This lengthening of Mo–O5 distance indicates 
trans influence of terminal oxo-oxygen atom bounded on molybdenum as described in 
literature [33]. The relative positions of the N and S atoms from thiosemicarbazone 
change upon complexation with molybdenum and vanadium, for example [34]. This 
event is accompanied with lengthening of C1–S1, C1–N1, N2–N3, C2–N3, C3–C4 and 
shortening of C1–N2, C2–C3, C4–O3 bonds (in comparison with ligands free form) 
which is expected because some of mentioned atoms are now involved in chelatation.  
Crystal packing of [MoO2L
2
(CH3OH)]·CH3OH (2a) complex (Fig. 4) is characterized 
with strong hydrogen bonding interactions of N–H···N type ( 22 (8)R ) and the N-H···O 
type ( 11 (3)D ). The terminal amino group has used its full potential for forming 
intermolecular interactions. The solvating methanol molecule is linked to the oxygen 
atom of cis-[MoO2]
2+
 unit by an O-H···O hydrogen bond. Additionally, the crystal 
packing is stabilized by great variety of weaker intermolecular interactions of C-H···O 
and C-H···π type. 
 
Figure 4.  
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TABLE 2,  
TABLE 3  
 
3.3. Study of molybdenum(VI)  complexes in solution  
 
3.3.1. NMR spectroscopy  
Although molybdenum(VI) complexes were well characterized in the solid state, their 
characterization in solution is necessary in order to evaluate the stability of studied 
complexes under biologically relevant conditions. However, poor solubility of 
molybdenum(VI) (1-3) complexes and related free ligands hampered NMR experiments 
in water; therefore spectra were recorded in DMSO-d6. The proton and carbon chemical 
shifts (Table 4, Scheme 2) were assigned by using one (
1
H and APT) and two-
dimensional (COSY, HSQC and HMBC) NMR experiments. The 
1
H and 
13
C chemical 
shifts of the third interacting site, i.e. C-5 are all downfield and appreciable smaller (2-3 
ppm). 
Scheme 2.  
TABLE 4 
 
The 
1
H and 
13
C chemical shift values are similar to those previously reported for the 
related ligands and their Mo(VI) complexes 17, 18. A relatively broad OH resonance 
was observed for all ligands at approximately 10 ppm, reflecting intramolecular 
hydrogen bonding interactions in DMSO-d6, which was consistent with the previous 
results. According to the chemical shifts, all ligands exist in the hydroxy-thione 
tautomeric form in DMSO-d6 as found in the solid state. 
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In the 
1
H spectra of of compounds 1-3 signals belonging to phenolic OH and NH-2 
protons are absent which is due to formation of the complexes. As a consequence, the 
NH-4 protons experience an up-field shift of approximately 1 ppm. The carbon 
chemical shifts exhibit much larger changes, up to 10.64 ppm as observed for C-1 atom 
in 2 and 13.96 ppm for C-3 in 1. These effects are down-field for the former and up-
field for the later site. The observed shielding and deshielding effects are a consequence 
of electron redistribution upon complexation. The total effect at C-3 is a superposition 
of a coordination-induced effect and the formation of an imine instead of a thiocarbonyl 
bond. 
 
3.3.2. Spectrophotometric properties of aqueous solutions of molybdenum(VI) 
complexes 1−8 in comparison to corresponding free ligands H2L
1
-H2L
8
 
 
We have chosen UV/Vis and fluorescence spectroscopy for further studies in 
aqueous solution since metal coordination usually has profound impact on the 
electronic properties of organic ligand. All studied complexes are poorly soluble in 
water, although significantly better than free ligands [16]. Therefore, for easier 
manipulation in further experiments, stock solutions of 1-8 complexes were prepared in 
DMSO at c = 5 ×10
-3 − 1 × 10-2 mol dm-3. For all experiments small aliquots of DMSO 
stock solutions were added into the aqueous medium to give homogeneous solutions 
with DMSO content of less than 5%. The UV/Vis spectra of 1-8 complexes (Fig. 5) are 
linearly dependent on the concentration of compounds up to 1 × 10-5 mol dm-3, except 
for the complex 7, which precipitated at c > 8 × 10-6 mol dm-3.   
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Figure 5.  
TABLE 5 
 
The UV/Vis spectra (Fig. 5, Table 5) of molybdenum complexes 1-8 resemble quite 
closely by shape to those of the corresponding ligands H2L
1
-H2L
8
 [16], differing only 
by values of molar extinction coefficients. However, temperature dependent changes of 
the UV/Vis spectra of 2-7 complexes and corresponding free ligands differed 
significantly (data not shown). 
All studied complexes 1-8, as well as corresponding free ligands H2L
1
-H2L
8
, exhibit 
strong fluorescence emission (Fig. 6), linearly dependent on concentration up to  
c = 8 × 10-6 mol dm-3.   
 
Figure 6.  
 
Comparison of UV/Vis (Fig. 5) and fluorescence emission (Fig. 6) spectra of free 
ligands [16] and their molybdenum complexes dissolved in water revealed in most 
cases distinct differences, pointing that molybdenum complexes didn’t completely 
dissociated into free ligands.  
In addition, temperature dependent changes in the UV/Vis and fluorescence spectra of 
free ligands and related molybdenum(VI) complexes, were in most cases significantly 
different. 
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Obtained results clearly indicate that most of Mo complexes upon dissolving in water 
do not completely dissociate into free ligand and Mo
VI
O2
2+
 cation. However, only 
determination of stability constants of Mo(VI) complexes under biologically relevant 
conditions can give exact information about percentage of complex dissociation. For 
this reason we have performed UV/Vis and fluorimetric titrations of free ligands with 
dioxobis(2,4-pentanedionato)molybdenum(VI) [MoO2(acac)2] in aqueous medium. 
 
3.3.3. Spectrophotometric titrations of free ligands with dioxobis(2,4-pentanedionato) 
molybdenum (VI)  [MoO2(acac)2] 
 
Addition of [MoO2(acac)2] yielded hypochromic changes in the UV/Vis spectra of 
aqueous solutions of free ligands H2L
1
-H2L
8 
. The most prominent changes were 
observed for free ligand H2L
1
 (Fig. 7). Furthermore, addition of [MoO2(acac)2]resulted 
in strong quenching of free ligands fluorescence (Fig. 8). Stability constants (Ks) and 
the stoichiometries of L/Mo complexes were obtained by processing the titration data 
with SPECFIT program [28] (Table 6). 
 
Figure 7.  
Figure 8.  
TABLE 6 
Results presented in Table 6 revealed that for all ligands except H2L
8
 best fit was 
obtained for 1:1 Mo:ligand stoichiometry, either as only possible result (H2L
1
 and 
H2L
6
) or in combination with 2:1 Mo:ligand stoichiometry (H2L
2
, H2L
3
, H2L
4
, H2L
5
, 
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H2L
7
). Processing of some titrations gave two equally possible solutions (H2L
3
, H2L
4
, 
H2L
5
, H2L
7
) among which only for H2L
5
 it was possible to neglect formation of 2:1 
Mo:ligand stoichiometry due to the exclusive result of UV/Vis titration. Therefore, 
according to here presented results it is not possible to distinguish for H2L
3
, H2L
4
, 
H2L
7
 whether one or two complexes are formed.  
Comparison of titration results (Table 6) with UV/Vis and fluorimetric spectra of 1-8 
complexes in water revealed several distinct differences between complexes prepared 
by titration and complexes resulting from dissolving the solid samples: a) batochromic 
shift of the free ligand UV/Vis spectrum observed in titration experiments (e.g. Fig. 7) 
was not present in comparison of UV/Vis spectrum of dissolved molybdenum complex 
1 with the UV/Vis spectrum of free H2L
1
; b) in UV/Vis titrations only hypochromic 
effects were observed, which does not agree with data presented in Table 5, in which 
some complexes have higher  values than corresponding free ligands; c) addition of 
[MoO2(acac)2] resulted in quenching of ligands fluorescence exclusively, in contrast to 
data presented on Fig. 8, according to which some complexes have stronger emission 
than corresponding free ligands. According to these differences, it is obvious that 
species resulting from dissolving solid complexes are not the same as obtained from 
titration results. Most probably the diketonate [MoO2(acac)2] was rapidly hydrolyzed in 
aqueous solution yielding different species as it was known from the literature [35]. 
Therefore, determined stability constants (Table 6) cannot be used to exactly calculate 
percentage of dissociation of 1-8 complexes upon dissolving them in water. Since there 
is no other experimental approach available to examine dissociation of 1-8 complexes 
in water, it is only possible to roughly estimate (according to logKs values in Table 6) 
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that at biologically relevant conditions (c([MoO2L
1−8
])= 10
-6
 − 10-5 mol dm-3) at least 
10% (H2L
1
, H2L
5
) up to 50% (H2L
2
, H2L
3
, H2L
4
, H2L
6
, H2L
7
, H2L
8
) was present in a 
form of complex with Mo(VI). 
 
3.4. Interactions of 1-8 complexes with ct-DNA 
Interactions of complexes 2 and 4 (chosen as the representatives since their free ligands 
H2L
2
 and H2L
4
 were previously studied for interactions with DNA [16]) with ct-DNA 
were studied by thermal denaturation experiments and UV/Vis titrations. 
Addition of ct-DNA didn’t yield any measurable change in the UV/Vis spectra of 2 and 
4, similar as observed for their free ligands H2L
2
 and H2L
4
. Furthermore, thermal 
denaturation experiments done at ratios r[2, 4] / [ct-DNA] = 0.3 didn’t alter thermal 
denaturation properties of ct-DNA.  
The obtained results suggest that complexes 2 and 4 do not interact with ct-DNA. This 
result would imply that introduction of positive charge (by Mo(VI)) does not increase 
affinity of neutral ligands H2L
2
 and H2L
4
 toward ct-DNA sufficiently for biological 
relevance. 
 
 
 
3.5. The effect of thiosemicarbazonato molybdenum(VI) complexes 1-8 on the 
proliferation of tumor and normal cells 
Complexes 1-8 were tested for their potential antiproliferative effects using MTT test 
(as described in the Experimental section) on a panel of 6 human cell lines, 5 of which 
 23 
were derived from different cancer types including HeLa (cervical carcinoma), MCF-7 
(breast carcinoma), SW620 (colon carcinoma), MiaPaCa-2 (pancreatic carcinoma), 
Hep-2 (laryngeal carcinoma) and one from normal diploid fibroblasts, WI 38 (Table 7). 
All tested compounds showed noticeable antiproliferative effect having IC50 values in 
the low micromolar, or submicromolar range (Table 7), whereby 5 and 7 had the most 
prominent activity. However, the activity of thiosemicarbazonato molybdenum(VI) 
complexes are almost completely identical to the activity of their corresponding ligands 
described previously [16]. Therefore, it seems that molybdenum does not improve the 
cytotoxic effect of thiosemicarbazones, which apparently have very strong activity on 
their own, or alternatively the fraction of 1-8 complexes is too small in the biological 
relevant conditions, to induce significant effects. 
 
TABLE 7 
 
4. Conclusions 
The new molybdenum(VI) complexes revealed that thiosemicarbazonato ligands are 
coordinated to molybdenum as tridentate ONS-donors. Octahedral coordination of each 
Mo atom in [MoO2L
2
(CH3OH)]·CH3OH (2a) in solid state was determined by X-ray 
crystallography and all complexes were in detail characterized by means of chemical 
and TG analyses and IR spectroscopy. In DMSO-d6 solution NMR spectra of 1-3 
complexes revealed distinct differences in comparison with corresponding free ligands. 
The characterisation of 1-8 complexes in aqueous medium by means of UV/Vis and 
fluorescence spectrophotometry revealed that upon dissolving 1-8 complexes in water, 
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most likely to some extent dissociation took place. Antiproliferative effects of 1-8 
complexes on the human cell lines were identical to the activity of their corresponding 
ligands described previously [16]. That could be attributed to either: a) partial 
dissociation of 1-8 complexes under biologically relevant conditions, resulting in 
concentration of 1-8 complexes too low for significant biological contribution; or b) the 
molybdenum(VI) complexes does not improve the cytotoxic effect of 
thiosemicarbazones, which apparently have very strong activity on their own. 
 
Acknowledgments 
We wish to thank Prof. N. Strukan for the collection of X-ray data for compounds 2a 
and H2L
2
. Financial support for this research was provided by Ministry of Science and 
Technology of the Republic of Croatia (Grants No. 119-1101342-1082, 119-1193079-
1084, 098-0982914-2918, 098-0982464-2514). 
 
Supplementary Material Available: 
Crystallographic data have been deposited with the CCDC, 12 Union Road, Cambridge, 
CB2 1EZ, UK (fax: +44-1223-366033; e-mail: deposit@ccdc.cam.ac.uk or 
www://www.ccdc.cam.ac.uk) and are available on request, quoting the deposition 
number 702874 for the compound H2L
2
 and 702875 for the compound 2a.  
 
 
 
 
 25 
References 
                                                 
[1] P. I. da S. Maia, F. R. Pavan, C. Q. F. Leite, S. S. Lemos, G. F. de Sousa, A. A. 
Batista, O. R. Nascimento, J. Ellena, E. E. Castellano, E. Niquet, V.  M. Deflon, 
Polyhedron 28 (2009) 398-406. 
[2] D. X. West, A. E. Liberta, S. B. Padhye, R. C. Chikate, P. B. Sonawane, A. S. 
Kunmbhar, R. G. Yerande, Coord. Chem. Rev. 123 (1993) 49-71. 
[3] D. Kovale-Demertzi, D. Domopoulou, M. Demertzis, C. P. Raptopoulou, A. Terzis, 
Polyhedron 13 (1994) 1917-1025. 
[4] D. B. Lovejoy, D. R. Richardson, Blood 100 (2002) 666-676. 
[5] N. Farrell, Coord. Chem. Rev. 232 (2002) 1-4. 
[6] M. Belicchi-Ferrari, F. Bisceglie, C. Casoli, S. Durot, I. Morgenstern-Badarau, G. 
Pelosi, E. Pilotti, S. Pinelli, P. Tarasconi, J. Med. Chem. 48 (2005) 1671-1675. 
[7] Z. Afrasiabi, E. Sinn, J. Chen, Y. Ma, A. L. Rheingold, L. N. Zakharov, N. Rath, S. 
Padhye, Inorg. Chim. Acta 357 (2004) 271-278. 
[8] R. R. Mendel,  F. Bittner, Biochim. Biophys. Acta – Mol. Cell Res. 1763 (2006) 
621-635.  
[9] C. D. Brondino, M. J. Romão, I. Moura, J. JG Moura, Curr. Opin. Chem. Biol. 10 
(2006) 109-114. 
[10] G. Hou, R. Dick, C. Zeng, G. J.Brewer, Transl. Res. 149 ( 2007) 260-4. 
[11] B. Hassouneh, M. Islam, T. Nagel, Q. Pan, S. D. Merajver, T. N. Teknos, Mol. 
Cancer Ther. 6 (2007) 1039-45. 
[12] H. Yanagiea,  A. Ogatab, S. Mitsuib, T. Hisaa, T. Yamaseb, M. Eriguchia, 
Biomed. Pharmacother. 60 (2006) 349-52. 
 26 
                                                                                                                                              
[13] T. Yamase,  Mol. Eng. 3 (1993) 241-262. 
[14] M. Cindrić, T. Kajfež  Novak, S. Kraljević,  M. Kralj, B. Kamenar, Inorg. Chim. 
Acta 359 (2006) 1673-1680.  
[15] P. Ghosh, O. J. D’Cruz, R. K. Narla, F. M. Uckun, Clin. Cancer Res. 6 (2000) 
1536-1545.  
[16] I. Đilović, M. Rubčić, V. Vrdoljak, S. Kraljević Pavelić, M. Kralj, I. Piantanida, 
M. Cindrić, Bioorg. Med. Chem. 16 (2008) 5189-5198. 
[17] M. Cindrić, V. Vrdoljak, N. Strukan, B. Kamenar,  Polyhedron 24 (2005) 369-376. 
[18] V. Vrdoljak, M. Cindrić, D. Matković-Čalogović, B. Prugovečki, P. Novak, B. 
Kamenar, Z. Anorg. Allg. Chem. 631 (2005) 928-936. 
[19] V. Vrdoljak, M. Cindrić, D. Milić, D. Matković-Čalogović, P. Novak, B. 
Kamenar, Polyhedron  24 (2005) 1717-1726. 
[20] G. J.-J. Chen, J. W. McDonald, W. E. Newton, Inorg. Chem. 15 (1976) 2612-
2615. 
[21] V.  Vrdoljak, I. Đilović, M. Cindrić, D. Matković-Čalogović, N. Strukan, A. 
Gojmerac-Ivšić, P. Novak, Polyhedron 28 (2009) 959 – 965. 
[22] Oxford Diffraction (2003). Oxford Diffraction Ltd., Xcalibur CCD system, 
CrysAlis Software system, Version 1.170. 
[23] G. M. Sheldrick, SHELXS, University of Göttingen, Germany, 1997. 
[24] G. M. Sheldrick, SHELXL97, University of Göttingen, Germany, 1997. 
[25] L. J. Farrugia, J. Appl. Crystallogr. 32 (1999) 837-838. 
[26] L. J. Farrugia, J. Appl. Crystallogr. 30 (1997) 565. 
 27 
                                                                                                                                              
[27] C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock, G. P. Shields, R. Taylor, 
M. Towler, J. van de Streek, J. Appl. Cryst. 39 (2006) 453-457. 
[28] Specfit   Global   Analysis, a Program for Fitting, Equilibrium and Kinetic 
Systems, Using Factor Analysis & Marquardt Minimization; a) M. Maeder, A. D. 
Zuberbuehler, Anal. Chem. 62 (1990) 2220-2224.; b) H. Gampp, M. Maeder, C .J. 
Meyer, A.D. Zuberbuehler, Talanta 32 (1985) 257-264. 
[29] N. Kathale, N. S. Rao, N. N. Rao, K. N. Munshi, Synth. React. Inorg. Met-Org. 
Chem. 31 (2001) 859-871. 
[30] S. Bhattacharjee, R. Bhattacharjee, J. Chem. Soc., Dalton Trans. (1992) 1357-1364 
[31] E. B. Seena, B. N. Bessy Raj, M. R. Prathapachandra Kurup, E. Suresh, J.  Chem. 
Cryst. 38 (2008) 93-96. 
[32] Cambridge Structural Database, V5.28, Cambridge Crystallographic Data Centre, 
12 Union Road, Cambridge, England, November 2006. 
[33] A. Rana, R. Dinda, P. Segupta, S. Ghosh, L. R. Falvello, Polyhedron 21 (2002) 
1023-1030. 
[34] M. Cindrić, M. Rubčić, I. Đilović, G. Giester, B. Kamenar, Croat. Chem. Acta 80 
(2007) 583-590. 
[35] M. R. Pedrosa, J. Escribano, R. Aguado, V. Díez, R. Sanz, F. J. Arnáiz, 
Polyhedron 26 (2007) 3695-3702. 
 
 
 
 
 28 
                                                                                                                                              
Table 1. Thermoanalytical data for the complexes [MoO2L]n, [MoO2L(CH3OH)]. 
 
Formula Comp. 
Loss of solvent Decomposition 
Temperature 
range (°C) 
Δm (%) 
found 
(calcd.) 
Temperature 
range (°C) 
Δm (%) 
found 
(calcd.) 
[MoO2(C12H16N4OS)]n 
1 
--- --- 212-475 
63.91 
(63.31) 
[MoO2(C12H16N4OS)(CH3OH)] 
1a 
30-90 
6.48 
(7.55) 
185-472 
66.21 
(66.09) 
[MoO2(C9H9N3O2S)]n 
2 
--- --- 255-542 
55.76 
(55.18) 
[MoO2(C9H9N3O2S)(CH3OH)] 
2a 
75-131 
8.46 
(8.36) 
273-469 
62.44 
(63.13) 
[MoO2(C12H9N3OS)]n 
3 
  176-586 
61.22 
(63.31) 
[MoO2(C12H9N3OS)(CH3OH)] 
3a 
130-152 
7.78 
(7.95) 
225-526 
64.31 
(64.50) 
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Table 2. General and crystal data, summary of intensity data collection and structure 
refinement for the H2L
2 
and [MoO2L
2
(CH3OH)]·CH3OH (2a). 
 H2L
2
 2a 
Empirical formula C9H11N3O2S C11H17MoN3O6S 
Formula weight 225.27 415.27 
Color Colourless Red 
Crystal system, space group Monoclinic, P21/c Monoclinic, P21/a 
Unit cell dimensions (Å, °)   
a 7.0724(14) 13.8987(2) 
b 14.700(3) 7.2884(2) 
c 10.787(2) 16.3552(3) 
β 108.46(3) 104.6120(10) 
Volume (Å3) 1063.7(4) 1603.18(6) 
Z 4 4 
Dcalc (g cm
-3
) 1.407 1.716 
μ (mm-1)   0.288 0.979 
F (000) 472 836 
Reflections collected/unique  3492/ 1785 9640 /2798 
Data/restraints/parameters 1785/0/170 2798/0/211 
Goodness-of-fit on F
2
 1.102 1.113 
R/wR [I>2σ(I)]* 0.0458/0.1272 0.0321/ 0.0749 
Largest diff. peak and hole (e Å−3) 0.201/−0.175 0.655/−0.636 
* 
R = ∑||Fo|-|Fc||/∑Fo,
 
w = 1/[σ2(Fo
2
)+(g1P)
2
+ g2P] where P = (Fo
2
+2Fc
2
)/3, S = Σ[w(Fo
2
 – 
Fc
2
)
2
/(Nobs – Nparam)]
1/2
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Table 3. Selected bond lengths (Å) and angles (°) for the H2L
2 
and 
[MoO2L
2
(CH3OH)]·CH3OH (2a). 
 H2L
2
 2a 
C1–S1 1.697(3) 1.758(3) 
C1–N1 1.320(4) 1.343(4) 
C1–N2 1.337(3) 1.310(4) 
C2–C3 1.467(4) 1.455(4) 
C2–N3 1.268(4) 1.298 
C3–C4 1.387(4) 1.399(4) 
C4–O3 1.356(3) 1.345(4) 
N2–N3 1.385(3) 1.401(3) 
Mo1–O1  1.727(2)  
Mo1–O2  1.704(2) 
Mo1–O3  1.922(2) 
Mo1–N3  2.273(3) 
Mo1–S1  2.4317(7) 
Mo1–O5   2.351(2) 
O1–Mo1–O2  105.26(12)   
O1–Mo1–O3  104.65(9) 
O1–Mo1–N3  156.41(10) 
O1–Mo1–O5  83.58(9) 
O1–Mo1–S1  90.20(7) 
O2–Mo1–O3  99.35(10) 
O2–Mo1–N3  95.29(11) 
O2–Mo1–O5  171.14(10) 
O2–Mo1–S1  95.72(8) 
O3–Mo1–N3  82.84(9) 
O3–Mo1–O5  78.49(8) 
O3–Mo1–S1  155.11(7) 
N3–Mo1–O5  75.95(8) 
N3–Mo1–S1  76.13(6) 
O5–Mo1–S1  83.58(6) 
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Table 4. 
1
H and 
13
C chemical shifts (ppm) of the ligands H2L
1
-H2L
3
 and their 
molybdenum(VI) complexes  1-3 in DMSO-d6. 
 
Comp. H2L
1
 1 H2L
2
 2 H2L
3
 3 
atom 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1
H 
13
C 
1 8.19 142.45 8.21 151.19 8.40 139.83 8.43 150.47 9.05 142.92 9.22 146.32 
2 11.07    11.39    11.38    
3  176.55  162.60  178.05  166.01  177.41  165.87 
4 7.87 
7.66 
 6.66  8.10 
7.88 
  6.95 8.20 
7.81 
 7.18  
5  158.26  160.38  146.34  148.57  156.49  159.70 
6 6.09 97.40 6.06 98.64  148.26  148.16 7.19 118.23 7.14 120.05 
7  150.20  151.88 6.96 113.19 7.10 115.15 7.88 132.35 7.99 133.91 
8 6.21 104.08 6.34 105.18 6.77 119.33 6.92 120.37  127.95  128.77 
9 7.52 129.12 7.28 134.60 7.53 118.52 7.15 124.41 7.85 128.56 7.92 129.09 
10  107.51  108.96  121.14  121.20 7.38 123.33 7.45 124.33 
11 3.33 43.94 3.70 43.84 3.81 56.25 3.77 55.60 7.56 127.75 7.61 128.23 
12 1.10 12.69 1.10 12.47     8.51 122.70 8.26 121.37 
13          131.40  132.25 
14          109.61  112.31 
OH 9.61    9.17    10.48    
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Table 5. Electronic absorption maxima and molar extinction coefficients of the ligands
a
 
H2L
1
-H2L
8
 and their molybdenum(VI) complexes 1-8 in water.  
 
 [MOO2L(CH3OH)] 
A
 H2L
 
 λmax / nm ε / mmol
-1
 cm
2
  λmax / nm ε / mmol
-1
 cm
2
 
1 368 56.26 ± 1.26 H2L
1
 368 40.98±1.57 
2 307 23.37 ± 0.28 H2L
2
 307 24.67±0.28 
3 326 
361 
25.17 ± 0.10 
27.91 ± 0.14 
H2L
3
 
326 
361 
24.42 ±0.26 
27.10 ± 0.30 
4 300 
325 
29.87 ± 0.11 
28.19 ± 0.12 
H2L
4
 
300 
325 
21.68 ± 0.07 
20.51 ± 0.06 
5 376 30.60 ± 1.49 H2L
5
 376 40.50 ± 1.53 
6 314 37.32 ± 0.62 H2L
6
 314 35.93 ± 1.26 
7 328 
363 
15.64 ± 0.54 
18.49 ± 0.81 
H2L
7
 
328 
363 
9.46 ± 0.41 
10.25 ± 0.59 
8 303 
329 
40.44 ± 0.33 
43.77 ± 0.35 
H2L
8
 
303 
329 
29.86 ± 0.42 
32.02 ± 0.48 
a
 Published data [16].  
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Table 6.  Binding constants (logKs)
a
 calculated by SPECFIT program [28]
 
for various 
Mo:ligand stoichiometries from the UV/Vis and fluorimetric titrations of free ligands 
with [MoO2(acac)2]. 
 UV/Vis titrations fluorimetric titrations 
ligand Mo:ligand logKs11 logβ Mo:ligand logKs11 logβ 
H2L
1
 1:1 4.42 ± 0.02  1:1 4.92 ± 0.05  
H2L
2
 1:1 and 2:1 6.10±0.42 9.66±0.39 
c
 
c
 
c
 
H2L
3
 
d
1:1 
d
 1:1 and 2:1 
3.94±0.07  
c c c 
3.94±0.27 7.99±0.3 
H2L
4
 
d
 1:1 
d
 1:1 and 2:1 
3.40±0.15  
c
 
c
 
c
 
4.28±0.48 8.29±0.34 
H2L
5
 
1:1 
 
5.25±0.03  d 1:1 4.74 ± 0.02  
  
d
 1:1 and 2:1 4.72 ± 0.03 8.01 ± 0.29 
H2L
6
 1:1 4.45±0.06   4.16 ± 0.04  
H2L
7
 
b
 
b
 
b
 
d
 2:1  10.17±0.03 
  
d
 1:1 and 2:1 4.10±0.32 10.12 ± 0.15 
H2L
8
 2:1  8.01±0.09 2:1  8.03 ±0.04 
a
 Given logKs values satisfied following criteria: i) correlation coeff. r>0.999, ii) no 
systematic deviation of experimental and calculated data; iii) under experimental 
conditions percentage of complex(es) formed was between 20 – 80 %.; b Precipitation; c 
Signal to noise ratio didn’t allow accurate experiment d Processing of titration data by 
SPECFIT [28]
 
 gave two gave two equally possible solutions. 
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Table 7. In vitro inhibition of complexes 1-8 on the growth of tumor cells and normal 
human fibroblasts (WI 38).  
Compd. 
IC50 (μM)
[a]
 
Hep-2 HeLa MiaPaCa-2 SW620 MCF-7 WI 38 
1 1±0.2 2±0,8 >5 3±1 0.2±0.4 0.2±0.02 
2 3.2±1 ≥5 0.6±0.4 ≥5 0.2±0.3 0.6±0.04 
3 ≥5 ≥5 >5 >5 >5 2±0.7 
4 >5 >5 >5 >5 ≥5 1±0.8 
5 0.6±0.08 0.7±0.2 0.5±0.2 0.7±0.1 0.7±0.02 0.6±0.2 
6 3±1 1±0.3 2±0.6 2±0.001 2±0.2 ≥5 
7 0.6±0.3 0.4±0.1 0.9±0.04 0.5±0.2 0.9±0.06 0.6±0.3 
8 2±0.07 2±0.1 3±0.5 2±0.1 2±0.2 2±1 
cisplatin 3±1 4±2 5 ± 2 8 ± 6 12 ± 5 21±15 
etoposide N.T.
 [b]
 3±1 15±14 20±3 50±20 N.T. [b] 
doxorubicin 0.04 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 0.1 ± 0.01 
 [a] - 
IC50; the concentration that causes a 50% reduction of the cell growth 
[b] – N.T.; not tested 
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Figure and Scheme captions 
 
Scheme 1. General synthetic procedure for studied molybdenum(VI) complexes, 
[MoO2L]n (1-8) and [MoO2L(CH3OH)] (1a-3a).  
Scheme 2. Numbering of C and H atoms. 
Figure 1. A view of the molecular structure of H2L
2
, showing atom labelling scheme.  
Displacement ellipsoids are drawn at the 50% probability level and H atoms are 
presented as spheres of arbitrary size.  
Figure 2. The crystal packing of H2L
2
 viewed down a axis. Layers of molecules are 
represented in different colours. Upper layer is shown in blue, bottom in red. Hydrogen 
bonds are represented as dashed sticks. Symmetry codes are mentioned above in the 
main text.  
Figure 3. View of the molecular structure of [MoO2L
2
(CH3OH)]·CH3OH (2a) with 
atom-labelling scheme. Thermal ellipsoids are shown at 50% probability level and 
hydrogen atoms are omitted for clarity. 
Figure 4. The crystal packing of [MoO2L
2
(CH3OH)]·CH3OH (2a). View is projected 
down the b axis. H atoms not involved in hydrogen bonding are omitted for clarity. 
Symmetry codes: i = 1/2−x, y−1/2, 1−z; ii = −x, 1−y, 1−z. 
Figure 5. The UV/Vis spectra of 1-8 complexes in water. 
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Figure 6. The fluorimetric spectra of 1-8 complexes and corresponding free ligands 
H2L
1
 -H2L
8
 in water (c = 5 × 10-6 mol dm-3 , exc see maxima at longer wavelengths in 
Table 5). 
Figure 7. A) UV/Vis titration of free ligand H2L
1
 (c = 1.29 × 10-5 mol dm-3) with 
[MoO2(acac)2] (c = 0 − 1.2 ×10
-4
 mol dm
-3
) in water; B) distribution diagram of species 
present during titration; C) agreement of experimental and calculated values for 1:1 
stoichiometry.  
Figure 8. A) Fluorimetric titration of free ligand H2L
1
 (c = 2.58 × 10-6 mol dm-3) with 
[MoO2(acac)2] ( c = 0 – 6.0 × 10
-5
 mol dm
-3
) in water; B) distribution diagram of 
species present during titration; C) agreement of experimental and calculated values for 
1:1 stoichiometry.   
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Figure 1. 
 
 
Figure 2. 
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Figure 3. 
 
Figure 4. 
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